TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - VERTEX PHARMACEUTICALS TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - VERTEX PHARMACEUTICALS Share Price
Certificat
DE000SY1ANA0
| Market Closed - Boerse Frankfurt Warrants 20:47:23 28/06/2024 BST | ||
| 13.32 EUR | +2.94% |
|
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 28/06/24 | 12.89 | -0.39% |
| 27/06/24 | 12.94 | -1.22% |
| 26/06/24 | 13.1 | -0.46% |
| 25/06/24 | 13.16 | +2.65% |
| 24/06/24 | 12.82 | -4.26% |
Real-time Boerse Frankfurt Warrants
Last update June 28, 2024 at 08:47 pm
More quotesStatic data
| Product type | Certificat Turbo |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SY1ANA |
| ISIN | DE000SY1ANA0 |
| Date issued | 05/06/2024 |
| Strike | 611.1 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 13.31 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 13.73 € |
|---|---|
| Lowest since issue | 11.5 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
468.7
USD
Average target price
468.3
USD
Spread / Average Target
-0.10%
- Stock Market
- Certificates
- Certificat
